-
1
-
-
0023747883
-
Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia
-
Casey DE, Christensen AV Eds, Berlin, Springer
-
Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV Eds, Psychopharmacology: current trends. Berlin, Springer 1988; 74-93.
-
(1988)
Psychopharmacology: Current Trends
, pp. 74-93
-
-
Casey, D.E.1
Keepers, G.A.2
-
2
-
-
0015684611
-
Exacerbation of psychopathology during treatment: Etiology
-
Ananth JV and Brahm E. Exacerbation of psychopathology during treatment: etiology. Compr Psychiatry 1973; 14: 563-568.
-
(1973)
Compr. Psychiatry
, vol.14
, pp. 563-568
-
-
Ananth, J.V.1
Brahm, E.2
-
3
-
-
0028296475
-
Motor and mental aspects of acute extrapyramidal syndromes
-
Casey DE. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand 1994; 89(suppl 380): 14-20.
-
(1994)
Acta Psychiatr. Scand.
, vol.89
, Issue.SUPPL. 380
, pp. 14-20
-
-
Casey, D.E.1
-
4
-
-
0035014928
-
Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care Psychiatric institution
-
Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care Psychiatric institution. Can J Psychiatry 2001; 46: 334-339.
-
(2001)
Can. J. Psychiatry
, vol.46
, pp. 334-339
-
-
Procyshyn, R.M.1
Kennedy, N.B.2
Tse, G.3
Thompson, B.4
-
5
-
-
0032909923
-
Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic
-
Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic J Clin Psychiatry 1999; 60(suppl 10): 20-30.
-
(1999)
J. Clin. Psychiatry
, vol.60
, Issue.SUPPL. 10
, pp. 20-30
-
-
Ereshefsky, L.1
-
6
-
-
0343207778
-
Five year study of benztropine (Cogentin) methanesulfonate: Outcome in three hundred two cases of paralysis agitans
-
Doshay LJ. Five year study of benztropine (Cogentin) methanesulfonate: outcome in three hundred two cases of paralysis agitans. JAMA 1956; 162: 1031-1034.
-
(1956)
JAMA
, vol.162
, pp. 1031-1034
-
-
Doshay, L.J.1
-
7
-
-
0000046430
-
Treatment in internal medicine: The management of Parkinson's disease
-
England AC Jr, Schwab RS. Treatment in internal medicine: the management of Parkinson's disease. AMA Arch Intern Med 1959; 104: 439-468.
-
(1959)
AMA Arch. Intern. Med.
, vol.104
, pp. 439-468
-
-
England Jr., A.C.1
Schwab, R.S.2
-
8
-
-
0023155125
-
Trihexyphenidyl abuse: Therapeutic implications for negative symptoms of schizophrenia?
-
Fish RZ. Trihexyphenidyl abuse: therapeutic implications for negative symptoms of schizophrenia? Acta Psychiatr Scand 1987; 75: 91-94.
-
(1987)
Acta Psychiatr. Scand.
, vol.75
, pp. 91-94
-
-
Fish, R.Z.1
-
10
-
-
3042591944
-
Kemadrin in the treatment of parkinsonism
-
Schwab RS, Chafetz ME. Kemadrin in the treatment of parkinsonism. Neurology 1955; 5: 273-277.
-
(1955)
Neurology
, vol.5
, pp. 273-277
-
-
Schwab, R.S.1
Chafetz, M.E.2
-
13
-
-
0021037217
-
Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: Overview and pharmacology
-
Allen RM. Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology. Clin Neuropharmacol 1983; 6(suppl 1): 64-73.
-
(1983)
Clin. Neuropharmacol.
, vol.6
, Issue.SUPPL. 1
, pp. 64-73
-
-
Allen, R.M.1
-
14
-
-
0022508283
-
Exacerbation of schizophrenia associated with amantadine
-
Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT. Exacerbation of schizophrenia associated with amantadine. Am J Psychiatry 1986; 143: 1170-1171.
-
(1986)
Am. J. Psychiatry
, vol.143
, pp. 1170-1171
-
-
Nestelbaum, Z.1
Siris, S.G.2
Rifkin, A.3
Klar, H.4
Reardon, G.T.5
-
15
-
-
0029414763
-
Twenty five years of amantadine therapy in Parkinson's disease
-
Danielczyk W. Twenty five years of amantadine therapy in Parkinson's disease. J Neural Transm 1995; Suppl 46: 399-405.
-
(1995)
J. Neural Transm.
, Issue.SUPPL. 46
, pp. 399-405
-
-
Danielczyk, W.1
-
16
-
-
0026751312
-
Amantadine as N-Methyl-D-Aspartate acid receptor antagonist: New possibilities for therapeutic applications?
-
Stoof JC, Booij J, Drukarch B. Amantadine as N-Methyl-D-Aspartate acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg 1992; 94: S4-S6.
-
(1992)
Clin. Neurol. Neurosurg.
, vol.94
-
-
Stoof, J.C.1
Booij, J.2
Drukarch, B.3
-
17
-
-
0014939890
-
Amantadine-dopamine interaction: Possible mode of action in parkinsonism
-
Grelak RP, Clark R, Stump JM, Vernier VG. Amantadine-dopamine interaction: possible mode of action in parkinsonism. Science 1970; 169: 203-204.
-
(1970)
Science
, vol.169
, pp. 203-204
-
-
Grelak, R.P.1
Clark, R.2
Stump, J.M.3
Vernier, V.G.4
-
19
-
-
0023697460
-
Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia
-
Wilbur R, Kulik FA, Kulik AV. Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 849-864.
-
(1988)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.12
, pp. 849-864
-
-
Wilbur, R.1
Kulik, F.A.2
Kulik, A.V.3
-
20
-
-
0025875851
-
Studies on the time course and efficacy of beta-blockers in neuroleptic-induced akathisia and the akathisia of idiopathic Parkinson's disease
-
Adler LA, Angrist B, Weinreb H, Rotrosen J. Studies on the time course and efficacy of beta-blockers in neuroleptic-induced akathisia and the akathisia of idiopathic Parkinson's disease. Psychopharmacol Bull 1991; 27: 107-111.
-
(1991)
Psychopharmacol. Bull.
, vol.27
, pp. 107-111
-
-
Adler, L.A.1
Angrist, B.2
Weinreb, H.3
Rotrosen, J.4
-
21
-
-
0023472847
-
Lipophilicity, hydrophylicity, and the central nervous system side effects of beta-blockers
-
Drayer DE. Lipophilicity, hydrophylicity, and the central nervous system side effects of beta-blockers. Pharmacotherapy 1987; 7:87-91.
-
(1987)
Pharmacotherapy
, vol.7
, pp. 87-91
-
-
Drayer, D.E.1
-
22
-
-
0023553727
-
Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs
-
McDewitt DG. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J 1987; 8(suppl M): 9-14.
-
(1987)
Eur. Heart J.
, vol.8
, Issue.SUPPL. M
, pp. 9-14
-
-
McDewitt, D.G.1
-
23
-
-
0027365770
-
Serum iron abnormalities in neuroleptic-induced akathisia in schizophrenic patients
-
Soni SD, Tench D, Routledge RC. Serum iron abnormalities in neuroleptic-induced akathisia in schizophrenic patients. Br J Psychiatry 1993; 163: 669-72.
-
(1993)
Br. J. Psychiatry
, vol.163
, pp. 669-672
-
-
Soni, S.D.1
Tench, D.2
Routledge, R.C.3
-
25
-
-
0023253865
-
Low serum iron status and akathisia
-
Brown KW, Glen SE, White T. Low serum iron status and akathisia. Lancet 1987; 1(8544): 1234-6.
-
(1987)
Lancet
, vol.1
, Issue.8544
, pp. 1234-1236
-
-
Brown, K.W.1
Glen, S.E.2
White, T.3
-
26
-
-
0009676668
-
Neuroleptic induced acute dystonia
-
Lang AE, Weiner WJ Eds, Mount Kisko, Futura
-
Casey DE. Neuroleptic induced acute dystonia. In: Lang AE, Weiner WJ Eds, Drug-induced movement disorders. Mount Kisko, Futura 1992; 21-40.
-
(1992)
Drug-induced Movement Disorders
, pp. 21-40
-
-
Casey, D.E.1
-
28
-
-
0015278467
-
The rabbit syndrome: A peculiar extrapyramidal reaction
-
Villeneuve A. The rabbit syndrome: a peculiar extrapyramidal reaction. Can Psychiatr Assoc J 1972; 17: 69-72.
-
(1972)
Can. Psychiatr. Assoc. J.
, vol.17
, pp. 69-72
-
-
Villeneuve, A.1
-
29
-
-
0019473480
-
The differential diagnosis of tardive dyskinesia
-
Casey DE. The differential diagnosis of tardive dyskinesia. Acta Psychiatr Scand 1981; 63(suppl 291): 71-87.
-
(1981)
Acta Psychiatr. Scand.
, vol.63
, Issue.SUPPL. 291
, pp. 71-87
-
-
Casey, D.E.1
-
30
-
-
3042541436
-
-
Eds Washington DC, American Psychiatric Press
-
Baldessarini RJ, Cole JO, Davis JM, Gardos G, Preskorn SH, Simpson GM, et al. Eds. Tardive Dyskinesia: A Task Force Report on Late Neurological Effects of Antipsychotic Drugs. Washington DC, American Psychiatric Press c1979.
-
(1979)
Tardive Dyskinesia: A Task Force Report on Late Neurological Effects of Antipsychotic Drugs
-
-
Baldessarini, R.J.1
Cole, J.O.2
Davis, J.M.3
Gardos, G.4
Preskorn, S.H.5
Simpson, G.M.6
-
31
-
-
0022600929
-
Integrating incidence and prevalence of tardive dyskinesia
-
Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986; 22(1):254-8.
-
(1986)
Psychopharmacol. Bull.
, vol.22
, Issue.1
, pp. 254-258
-
-
Kane, J.M.1
Woerner, M.2
Borenstein, M.3
Wegner, J.4
Lieberman, J.5
-
32
-
-
0021929136
-
Spontaneous and tardive dyskinesias: Clinical and laboratory studies
-
Apr
-
Casey DE. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiatry 1985 Apr; 46(4 pt 2): 42-7.
-
(1985)
J. Clin. Psychiatry
, vol.46
, Issue.4 PART 2
, pp. 42-47
-
-
Casey, D.E.1
-
33
-
-
3042551763
-
Paradoxical tardive dyskinesia
-
Joseph AB, Young RR Eds, Boston, Blackwell
-
Casey DE. Paradoxical tardive dyskinesia. In: Joseph AB, Young RR Eds, Movement disorders of neurology and neuropsychiatry. Boston, Blackwell 1992; 67-69.
-
(1992)
Movement Disorders of Neurology and Neuropsychiatry
, pp. 67-69
-
-
Casey, D.E.1
-
34
-
-
0017654351
-
Pharmacological characterization of tardive dyskinesia
-
Casey DE, Denny D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology 1977; 54: 1-8.
-
(1977)
Psychopharmacology
, vol.54
, pp. 1-8
-
-
Casey, D.E.1
Denny, D.2
-
35
-
-
0015966498
-
Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia
-
Gerlach J, Reisby N, Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacology 1974; 34: 21-35.
-
(1974)
Psychopharmacology
, vol.34
, pp. 21-35
-
-
Gerlach, J.1
Reisby, N.2
Randrup, A.3
-
36
-
-
0003408017
-
Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association
-
American Psychiatric Association. Task Force on Tardive Dyskinesia. Washington, DC, American Psychiatric Association
-
American Psychiatric Association. Task Force on Tardive Dyskinesia. Tardive Dyskinesia: a Task Force Report of the American Psychiatric Association. Washington, DC, American Psychiatric Association 1992.
-
(1992)
-
-
-
37
-
-
0029907320
-
Negative symptoms, congnitive dysfunction tardive akathisia and tardive dyskinesia
-
Sachdev P, Hume F, Toohey P, Doutney C. Negative symptoms, congnitive dysfunction tardive akathisia and tardive dyskinesia. Acta Psychiatr Scand 1996; 91: 451-459.
-
(1996)
Acta Psychiatr. Scand.
, vol.91
, pp. 451-459
-
-
Sachdev, P.1
Hume, F.2
Toohey, P.3
Doutney, C.4
-
40
-
-
84880510965
-
Dystonic reactions following neuroleptics: Time course and proposed mechanisms
-
Garver DL, Davis JM, Dekirmenjian H, Ericksen S, Gosengeld L, Haraszti J. Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacology 1976: 47: 199-201.
-
(1976)
Psychopharmacology
, vol.47
, pp. 199-201
-
-
Garver, D.L.1
Davis, J.M.2
Dekirmenjian, H.3
Ericksen, S.4
Gosengeld, L.5
Haraszti, J.6
-
44
-
-
0025975251
-
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia
-
Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4: 109-120.
-
(1991)
Schizophr. Res.
, vol.4
, pp. 109-120
-
-
Casey, D.E.1
-
45
-
-
3042589822
-
Treatment of extrapyramidal side effects
-
Schatzberg AF, Nemeroff CB Eds, Washington, DC, American Psychiatric Publishing, Inc
-
Stanilla JK, Simpson GM. Treatment of extrapyramidal side effects. In: Schatzberg AF, Nemeroff CB Eds, Essentials of Clinical Psychopharmacology. Washington, DC, American Psychiatric Publishing, Inc. 2001; 155-182.
-
(2001)
Essentials of Clinical Psychopharmacology
, pp. 155-182
-
-
Stanilla, J.K.1
Simpson, G.M.2
-
46
-
-
0009026129
-
Adverse psychotropic drug-drug interactions
-
Kane JM, Lieberman JA Eds, New York, Guilford
-
Leipzig RM, Mendelowitz A. Adverse psychotropic drug-drug interactions. In: Kane JM, Lieberman JA Eds, Adverse Effects of Psychotropic Drugs. New York, Guilford 1992; 13-76.
-
(1992)
Adverse Effects of Psychotropic Drugs
, pp. 13-76
-
-
Leipzig, R.M.1
Mendelowitz, A.2
-
47
-
-
0021053879
-
The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs
-
McEvoy JP. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol 1983; 3: 288-302.
-
(1983)
J. Clin. Psychopharmacol.
, vol.3
, pp. 288-302
-
-
McEvoy, J.P.1
-
48
-
-
0028998465
-
Interactions between antipsychotic and antihypertensive drugs
-
Jun
-
Markowitz JS, Wells BG, Carson WH. Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 1995 Jun; 29(6): 603-9.
-
(1995)
Ann. Pharmacother.
, vol.29
, Issue.6
, pp. 603-609
-
-
Markowitz, J.S.1
Wells, B.G.2
Carson, W.H.3
-
49
-
-
0015177350
-
Complications of psychotropic medications in high dosage
-
Warnes H, Ananth JV. Complications of psychotropic medications in high dosage. Psychiatr Q 1971; 45: 87-92.
-
(1971)
Psychiatr. Q.
, vol.45
, pp. 87-92
-
-
Warnes, H.1
Ananth, J.V.2
-
50
-
-
12244279032
-
Effect of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: A double blind placebo controlled study
-
Kumari V, Zachariah E, Galea A, Jones HC, Das M, Mehotra R, et al. Effect of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double blind placebo controlled study. J Psychopharmacol 17: 89-95, 2003.
-
(2003)
J. Psychopharmacol.
, vol.17
, pp. 89-95
-
-
Kumari, V.1
Zachariah, E.2
Galea, A.3
Jones, H.C.4
Das, M.5
Mehotra, R.6
-
51
-
-
0023885592
-
Differential memory function with dopaminergic versus anticholinergic treatment of drug induced extrapyramidal symptoms
-
Fayen M, Goldman MB, Moulthrop MA, Luchins DJ. Differential memory function with dopaminergic versus anticholinergic treatment of drug induced extrapyramidal symptoms. Am J Psychiatry 1988; 145: 483-486.
-
(1988)
Am. J. Psychiatry
, vol.145
, pp. 483-486
-
-
Fayen, M.1
Goldman, M.B.2
Moulthrop, M.A.3
Luchins, D.J.4
-
52
-
-
0025914326
-
Relationhsips between medication treatments and neuropsychological test performance in schizophrenia
-
Sweeney JA, Keilp JG, Haas GL, Hill J, Weiden PJ. Relationhsips between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 1991; 37: 297-308.
-
(1991)
Psychiatry Res.
, vol.37
, pp. 297-308
-
-
Sweeney, J.A.1
Keilp, J.G.2
Haas, G.L.3
Hill, J.4
Weiden, P.J.5
-
53
-
-
0033118149
-
Neuroleptic induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia
-
Krausz M, Moritz SH, Naber D, Lambert M, Andresen B. Neuroleptic induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia. Eur Psychiatry 1999; 14: 84-88.
-
(1999)
Eur. Psychiatry
, vol.14
, pp. 84-88
-
-
Krausz, M.1
Moritz, S.H.2
Naber, D.3
Lambert, M.4
Andresen, B.5
-
54
-
-
0018913664
-
Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism
-
Burnett GB, Prange AJ Jr, Wilson IC, Joliff LA, Creese IC, Synder SH. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. Neuropsychobiology 1980; 6(2): 109-20.
-
(1980)
Neuropsychobiology
, vol.6
, Issue.2
, pp. 109-120
-
-
Burnett, G.B.1
Prange Jr., A.J.2
Wilson, I.C.3
Joliff, L.A.4
Creese, I.C.5
Synder, S.H.6
-
55
-
-
0020352791
-
Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics
-
Chouinard G, Steinberg S. Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6(4-6): 571-8.
-
(1982)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.6
, Issue.4-6
, pp. 571-578
-
-
Chouinard, G.1
Steinberg, S.2
-
56
-
-
0033782696
-
Abuse potential of anticholinergics
-
Dose M, Tempal HD. Abuse potential of anticholinergics. Pharmacopsychiatry 2000, 33(suppl 1): 43-46.
-
(2000)
Pharmacopsychiatry
, vol.33
, Issue.SUPPL. 1
, pp. 43-46
-
-
Dose, M.1
Tempal, H.D.2
-
57
-
-
0027533878
-
Memory and cognitive impairments in a case of long term trihexyphenidyl abuse
-
Kajimura N, Mizuki Y, Kai S, Suetsugi M, Yamada M, Okuma T. Memory and cognitive impairments in a case of long term trihexyphenidyl abuse. Pharmacopsychiatry 1993; 26: 59-62.
-
(1993)
Pharmacopsychiatry
, vol.26
, pp. 59-62
-
-
Kajimura, N.1
Mizuki, Y.2
Kai, S.3
Suetsugi, M.4
Yamada, M.5
Okuma, T.6
-
58
-
-
0013999468
-
Perphenazine-benztropic treatment of newly admitted psychiatric patients
-
Hanlon TE, Schoenrich C, Freinek W, Turek I, Kurland AA. Perphenazine-benztropic treatment of newly admitted psychiatric patients. Psychopharmacologia 1966; 9: 328-339.
-
(1966)
Psychopharmacologia
, vol.9
, pp. 328-339
-
-
Hanlon, T.E.1
Schoenrich, C.2
Freinek, W.3
Turek, I.4
Kurland, A.A.5
-
59
-
-
0022445363
-
Anticholinergic agents in the prophylaxis of neuroleptic induced dystonic reactions: A prospective study
-
Sramek JJ, Simpson GM, Morrison RL, Heiser JF. Anticholinergic agents in the prophylaxis of neuroleptic induced dystonic reactions: a prospective study. J Clin Psychiatry 1986; 47: 305-309.
-
(1986)
J. Clin. Psychiatry
, vol.47
, pp. 305-309
-
-
Sramek, J.J.1
Simpson, G.M.2
Morrison, R.L.3
Heiser, J.F.4
-
60
-
-
0026085963
-
Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects
-
Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991; 148: 85-89.
-
(1991)
Am. J. Psychiatry
, vol.148
, pp. 85-89
-
-
Keepers, G.A.1
Casey, D.E.2
-
61
-
-
0020629612
-
Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes
-
Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983; 40: 1113-1117.
-
(1983)
Arch. Gen. Psychiatry
, vol.40
, pp. 1113-1117
-
-
Keepers, G.A.1
Clappison, V.J.2
Casey, D.E.3
-
62
-
-
0018762596
-
Benztropine prophylaxis of dystonic reactions
-
Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacologia 1979; 61: 261-262.
-
(1979)
Psychopharmacologia
, vol.61
, pp. 261-262
-
-
Stern, T.A.1
Anderson, W.H.2
-
63
-
-
0020374194
-
Extrapyramidal side effects and oral haloperidol: An analysis of explanatory patient and treatment characteristics
-
Moleman P, Schmitz PSM, Ladee GA. Extrapyramidal side effects and oral haloperidol: An analysis of explanatory patient and treatment characteristics. J Clin Psychiatry 1982; 43: 492-496.
-
(1982)
J. Clin. Psychiatry
, vol.43
, pp. 492-496
-
-
Moleman, P.1
Schmitz, P.S.M.2
Ladee, G.A.3
-
64
-
-
0014842629
-
Effect of withdrawal of antiparkinsonian medication on chronically hospitalized psychiatric patients
-
1970
-
Ananth JV, Horodesky S, Lehmann HE, Ban TA. Effect of withdrawal of antiparkinsonian medication on chronically hospitalized psychiatric patients. Laval Med 1970; 41: 934-938, 1970.
-
(1970)
Laval Med.
, vol.41
, pp. 934-938
-
-
Ananth, J.V.1
Horodesky, S.2
Lehmann, H.E.3
Ban, T.A.4
-
65
-
-
0017641717
-
Extrapyramidal side effects in chlorpromazine recipients: Emergence according to benztropine prophylaxis
-
Swett C Jr, Cole JO, Shapiro S, Slone D. Extrapyramidal side effects in chlorpromazine recipients: emergence according to benztropine prophylaxis. Arch Gen Psychiatry 1977; 34(8): 942-3.
-
(1977)
Arch. Gen. Psychiatry
, vol.34
, Issue.8
, pp. 942-943
-
-
Swett Jr., C.1
Cole, J.O.2
Shapiro, S.3
Slone, D.4
-
67
-
-
3042642574
-
Reversibility of drug induced parkinsonism
-
Cahan RB, Parrish DD. Reversibility of drug induced parkinsonism. Am J Psychiatry 1960; 116: 1022-1023.
-
(1960)
Am. J. Psychiatry
, vol.116
, pp. 1022-1023
-
-
Cahan, R.B.1
Parrish, D.D.2
-
68
-
-
0017086537
-
Comparison of benztropine mesylate and amantadine HCl in neuroleptic induced extrapyramidal symptoms
-
Stenson RL, Donlon PT, Meyer JE. Comparison of benztropine mesylate and amantadine HCl in neuroleptic induced extrapyramidal symptoms. Compr Psychiatry 1976; 17: 763-768.
-
(1976)
Compr. Psychiatry
, vol.17
, pp. 763-768
-
-
Stenson, R.L.1
Donlon, P.T.2
Meyer, J.E.3
-
69
-
-
0015323715
-
Evaluating the long term need for antiparkinsoniuan drugs by chronic schizophrenics
-
Klett CJ, Point P, Caffey E. Evaluating the long term need for antiparkinsoniuan drugs by chronic schizophrenics. Arch Gen Psychiatry 1972; 26: 374-379.
-
(1972)
Arch. Gen. Psychiatry
, vol.26
, pp. 374-379
-
-
Klett, C.J.1
Point, P.2
Caffey, E.3
-
71
-
-
0016030988
-
The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients
-
McClelland HA, Blessed G, Bhate S, Ali N, Clarke PA. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. Br J Psychiatry 1974; 124: 154-159.
-
(1974)
Br. J. Psychiatry
, vol.124
, pp. 154-159
-
-
McClelland, H.A.1
Blessed, G.2
Bhate, S.3
Ali, N.4
Clarke, P.A.5
-
72
-
-
0015108222
-
Lack of indication for use of antiparkinson medication. A follow-up study
-
Aug
-
Pecknold JC, Ananth JV, Ban TA, Lehmann HE. Lack of indication for use of antiparkinson medication. A follow-up study. Dis Nerv Syst 1971 Aug; 32(8): 538-41.
-
(1971)
Dis. Nerv. Syst
, vol.32
, Issue.8
, pp. 538-541
-
-
Pecknold, J.C.1
Ananth, J.V.2
Ban, T.A.3
Lehmann, H.E.4
-
73
-
-
0020587170
-
Changes in extrapyramidal symptoms following anticholinergic drug withdrawal
-
Perenyi A, Gardos G, Samu I, Kallos M, Cole JO. Changes in extrapyramidal symptoms following anticholinergic drug withdrawal. Clin Neuropharmacol 1983; 6: 55-61.
-
(1983)
Clin. Neuropharmacol.
, vol.6
, pp. 55-61
-
-
Perenyi, A.1
Gardos, G.2
Samu, I.3
Kallos, M.4
Cole, J.O.5
-
74
-
-
0020677739
-
The abrupt withdrawal of antiparkinsonian drugs in mentally handicapped patients
-
Carter G. The abrupt withdrawal of antiparkinsonian drugs in mentally handicapped patients. Br J Psychiatry 1983; 142: 166-168.
-
(1983)
Br. J. Psychiatry
, vol.142
, pp. 166-168
-
-
Carter, G.1
-
75
-
-
0025160813
-
Is maintenance antiparkinsonina treatmetn necessary?
-
Comaty JE, Janicak PC, Rajaratnam J, Sharma RP, Baker D, Davis JM. Is maintenance antiparkinsonina treatmetn necessary? Psychopharmacol Bull 1980; 26: 267-271.
-
(1980)
Psychopharmacol. Bull.
, vol.26
, pp. 267-271
-
-
Comaty, J.E.1
Janicak, P.C.2
Rajaratnam, J.3
Sharma, R.P.4
Baker, D.5
Davis, J.M.6
-
76
-
-
0026005852
-
Prophylactic antiparkinsonian druguse II, Withdrawal after long term maintenance therapy
-
Lavin MR, Rifkin A. Prophylactic antiparkinsonian druguse II, Withdrawal after long term maintenance therapy. J Clin Pharmacol 1991; 31: 769-777.
-
(1991)
J. Clin. Pharmacol.
, vol.31
, pp. 769-777
-
-
Lavin, M.R.1
Rifkin, A.2
-
78
-
-
0013797455
-
Treatment of phenothiazine induced parkinsonism with biperdin
-
Lapolla A, Nash LR. Treatment of phenothiazine induced parkinsonism with biperdin. Curr Ther Res Clin Exp 1965; 7: 536-541.
-
(1965)
Curr. Ther. Res. Clin. Exp.
, vol.7
, pp. 536-541
-
-
Lapolla, A.1
Nash, L.R.2
-
79
-
-
0032946164
-
Gradual withdrawal of long term anticholinergic antiparkinsonian medication in Chinese patients with chronic schizophrenia
-
Ungvari GS, Chui HF, Lam LC, Pang AH, Li SW, Leung T. Gradual withdrawal of long term anticholinergic antiparkinsonian medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol 1999; 19: 141-148.
-
(1999)
J. Clin. Psychopharmacol.
, vol.19
, pp. 141-148
-
-
Ungvari, G.S.1
Chui, H.F.2
Lam, L.C.3
Pang, A.H.4
Li, S.W.5
Leung, T.6
-
80
-
-
0032973854
-
Managing antipsychotic induced parkinsonism
-
Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic induced parkinsonism. Drug Safety 1999; 20: 269-275.
-
(1999)
Drug Safety
, vol.20
, pp. 269-275
-
-
Mamo, D.C.1
Sweet, R.A.2
Keshavan, M.S.3
-
81
-
-
0027364110
-
Efficacy of maintenance use of anticholinergic agents
-
Double DB, Warren GC, Evans M, Rowlands MP, Efficacy of maintenance use of anticholinergic agents. Acta Psychiatr Scand 1993; 88: 381-384.
-
(1993)
Acta Psychiatr. Scand.
, vol.88
, pp. 381-384
-
-
Double, D.B.1
Warren, G.C.2
Evans, M.3
Rowlands, M.P.4
-
82
-
-
0029063672
-
Antiparkinsonian drugs in neuroleptic teatment: Comparative study of progressive and abrupt withdrawal
-
Ali BH, Dogui M, Ammou BS, Loo H. Antiparkinsonian drugs in neuroleptic teatment:comparative study of progressive and abrupt withdrawal. Encephale 1995; 21: 209-215.
-
(1995)
Encephale
, vol.21
, pp. 209-215
-
-
Ali, B.H.1
Dogui, M.2
Ammou, B.S.3
Loo, H.4
-
83
-
-
0033055650
-
Psychotropic drug prescription in a psychiatric university hospital
-
Voirol P, Robert PA, Meister P, Oros I, Baumann P. Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 1999; 32: 29-37.
-
(1999)
Pharmacopsychiatry
, vol.32
, pp. 29-37
-
-
Voirol, P.1
Robert, P.A.2
Meister, P.3
Oros, I.4
Baumann, P.5
-
85
-
-
0021739964
-
A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital
-
Edwards S, Kumar V. A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital. Br J Psychiatry 1984; 145: 502-7.
-
(1984)
Br. J. Psychiatry
, vol.145
, pp. 502-507
-
-
Edwards, S.1
Kumar, V.2
-
87
-
-
0019858508
-
Adverse effects of antiparkinson drug withdrawal
-
Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 1981; 138: 1567-1571.
-
(1981)
Am. J. Psychiatry
, vol.138
, pp. 1567-1571
-
-
Jellinek, T.1
Gardos, G.2
Cole, J.O.3
-
88
-
-
0017398217
-
Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication
-
Jellinelk T. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Dis Nerv Syst 1977; 38(5): 353-5.
-
(1977)
Dis. Nerv. Syst.
, vol.38
, Issue.5
, pp. 353-355
-
-
Jellinelk, T.1
-
89
-
-
0018943605
-
Abuse of the antiparkinson drugs: A review of the literature
-
Smith JM. Abuse of the antiparkinson drugs: a review of the literature. J Clin Psychiatry 1980; 41(10): 351-4.
-
(1980)
J. Clin. Psychiatry
, vol.41
, Issue.10
, pp. 351-354
-
-
Smith, J.M.1
-
90
-
-
0029829013
-
Trihexyphenidyl (Artane) abuse in schizophrenic patients
-
Zemishlany Z, Aizenberg D, Weiner Z, Weizman A. Trihexyphenidyl (Artane) abuse in schizophrenic patients. Int Clin Psychopharmacol 1996; 11(3): 199-202.
-
(1996)
Int. Clin. Psychopharmacol.
, vol.11
, Issue.3
, pp. 199-202
-
-
Zemishlany, Z.1
Aizenberg, D.2
Weiner, Z.3
Weizman, A.4
-
91
-
-
0031037331
-
Trihexyphenidyl withdrawal encephalopathy
-
Johkura K, Matsumoto S, Hasegawa O, Kuroiwa Y. Trihexyphenidyl withdrawal encephalopathy. Ann Neurol 1997; 41(1): 133-4.
-
(1997)
Ann. Neurol.
, vol.41
, Issue.1
, pp. 133-134
-
-
Johkura, K.1
Matsumoto, S.2
Hasegawa, O.3
Kuroiwa, Y.4
-
92
-
-
0033759895
-
Insomnia related to biperidin withdrawal in two schizophrenic patients
-
Hirose S. Insomnia related to biperidin withdrawal in two schizophrenic patients. Int J Clin Psychopharmacol 2000; 15: 357-359.
-
(2000)
Int. J. Clin. Psychopharmacol.
, vol.15
, pp. 357-359
-
-
Hirose, S.1
-
93
-
-
0037278185
-
Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders
-
Luedtkea RR, Mach RH. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Design 2003; 9(8): 643-71.
-
(2003)
Curr. Pharm. Design
, vol.9
, Issue.8
, pp. 643-671
-
-
Luedtkea, R.R.1
Mach, R.H.2
-
94
-
-
0036250086
-
NR2B selective NMDA receptor antagonists
-
Nikam SS, Meltzer LT. NR2B selective NMDA receptor antagonists. Curr Pharm Design 2002; 8(10): 845-55.
-
(2002)
Curr. Pharm. Design
, vol.8
, Issue.10
, pp. 845-855
-
-
Nikam, S.S.1
Meltzer, L.T.2
-
95
-
-
0036242431
-
Progress in the development of selective nitric oxide synthase (NOS) inhibitors
-
Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Design 2002; 8(3): 177-200.
-
(2002)
Curr. Pharm. Design
, vol.8
, Issue.3
, pp. 177-200
-
-
Salerno, L.1
Sorrenti, V.2
Di Giacomo, C.3
Romeo, G.4
Siracusa, M.A.5
|